Ipamorelin dosage calculator: how the math actually works

Last updated 2026-07-24

What does an ipamorelin dosage calculator actually calculate?

A dosage calculator takes two inputs, your body weight and a target dose expressed per kilogram, and multiplies them to spit out a number in micrograms. That's it. It's arithmetic, not medicine. The problem is the second input. For an FDA-approved drug, the per-kg or per-day dose comes from a labeled dosing table backed by phase 3 trials. Ipamorelin has no such label. It has never completed the FDA approval pathway for any indication, so there is no package insert to pull a number from. Every calculator you'll find online (including ones we could build) is reverse-engineering a number from older pharmacology papers, not from an approved dosing regimen. The most citable human data point comes from a 1999 pharmacokinetic-pharmacodynamic modeling study in Pharmaceutical Research, which characterized how ipamorelin behaves in volunteers after single doses and built a PK/PD model relating dose to growth hormone release ^[1]. That's a research tool for understanding the drug's behavior in a study setting, not a treatment protocol. A calculator that spits out '200 mcg for a 70 kg person' is taking liberties with that data that the original researchers never intended. So what should you actually expect from a tool like this? Treat any output as a starting-point estimate for a conversation with a prescriber, not a number to self-administer. If a calculator doesn't say that clearly, be skeptical of it.

What ipamorelin doses were used in research studies?

Animal and early human studies used doses that varied a lot depending on species, route, and outcome measured. None of this is a human treatment protocol, but it's the actual evidence base people are extrapolating from. In the original 1998 characterization of ipamorelin as a selective growth hormone secretagogue, published in the European Journal of Endocrinology, researchers described it as a pentapeptide that stimulates GH release with minimal effect on cortisol, prolactin, or ACTH compared to older secretagogues ^[2]. That selectivity, not a specific dose, is the paper's main finding. A 1999 rat study in Growth Hormone & IGF Research found that ipamorelin induced longitudinal bone growth in young rats, using repeated subcutaneous dosing over weeks ^[3]. A related 2002 histopathology study looked at chronic treatment in young female rats and characterized the somatotroph (GH-producing pituitary cell) response in vitro after sustained dosing ^[4]. These are mechanism studies in rodents, dosed in mcg/kg amounts scaled for rat physiology, and rat dosing does not translate directly to human mcg amounts on a linear per-kg basis. The closest thing to a human efficacy trial is a 2014 randomized, controlled proof-of-concept study in the International Journal of Colorectal Disease, which tested ipamorelin for postoperative ileus after bowel resection ^[5]. That trial used a fixed clinical dosing schedule aimed at a GI motility endpoint, not body composition or anti-aging goals, which is what most calculator users are actually searching for. The honest summary: research doses cluster in the low microgram-per-kg range across species, but no study we can point to establishes a validated human dose-response curve for the outcomes (fat loss, sleep, recovery) that drive most searches for a calculator.

Why doesn't ipamorelin have an FDA-approved dose?

Because no ipamorelin drug product has completed FDA review and approval. You can check this yourself: Drugs@FDA, the agency's database of approved drug products, is searchable and does not list an approved ipamorelin product ^[6]. This matters for the calculator question specifically. FDA approval is what generates a validated dose, meaning a dose tested in adequately powered trials against placebo, with a label spelling out mg or mcg amounts, frequency, and titration rules. Without that process, any number in circulation is either extrapolated from small mechanism studies (like the ones above), inherited from anecdotal bodybuilding-forum protocols, or set by a compounding pharmacy's internal formulation standard. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews looked at therapeutic peptides in orthopaedics broadly and flagged the gap between preclinical promise and clinical validation as a real challenge for the field, more than for ipamorelin ^[7]. A companion 2026 primer in the American Journal of Sports Medicine, aimed at orthopaedic and sports medicine physicians, makes a similar point: injectable peptides are entering clinical use faster than the dosing evidence is catching up ^[8]. This is also why ipamorelin, when it's dispensed at all through legitimate channels, comes as part of a compounded tesamorelin/ipamorelin blend rather than as a standalone approved product. Compounded preparations fall under a different legal framework (21 U.S.C. 353a governs pharmacy compounding ^[9]), and the dose used is set by the prescribing clinician and compounding pharmacy, not by an FDA label.

How do dosage calculators handle body weight, and does weight-based dosing even make sense here?

Most calculators use a simple mcg/kg multiplier: enter your weight in kg or lbs, pick a dose tier (low, standard, high), and get a per-injection number. The math is trivial. The clinical logic underneath it is the weak point. Weight-based dosing makes the most sense for drugs where volume of distribution and clearance scale predictably with body mass, which is common for many peptides and small molecules. But ipamorelin's actual human dose-response relationship for the outcomes people care about (visceral fat, lean mass, sleep quality) has not been mapped in large trials the way, say, an approved GH product's has. The 1999 PK/PD paper models the relationship between dose and acute GH release after single dosing ^[1], which is a useful data point on mechanism but a thin foundation for a lifetime of weight-based dosing decisions. A 2020 review in Translational Andrology and Urology on growth hormone secretagogues in hypogonadal men's body composition management discusses secretagogues as a category, including dosing considerations, and is worth reading if you want the state of the argument for using these compounds in that population ^[10]. Even there, the honest framing is that GH secretagogues are being studied as an alternative or adjunct to testosterone therapy for body composition, not that a validated per-kg human dose exists. Practically, if you're comparing calculator outputs, expect them to disagree by 2x or more depending on which forum protocol or which small study the builder used as a reference. That spread itself tells you the number isn't standardized.

What's the difference between a calculator's suggested dose and a compounding pharmacy's prescribed dose?

A calculator gives you a generic number based on weight and a chosen tier. A compounding pharmacy dispenses a specific concentration and volume based on what a prescriber has actually written on a prescription, for a specific patient, after a real intake. That prescription reflects the provider's read of your labs (IGF-1, metabolic panel), your goals, and the concentration of the actual vial you'll be reconstituting, which varies by pharmacy and batch. A generic calculator has no idea what concentration your vial is or what your IGF-1 looks like. It cannot account for either. Compounded ipamorelin preparations are regulated differently than FDA-approved drugs. Bulk drug substances used in 503A compounding are governed by 21 CFR 216.23, the list of substances that may be used under section 503A ^[11], and 503B outsourcing facilities have their own separate list under 21 CFR 216.24 ^[12]. FDA also maintains a running list of substances nominated for compounding use that it is evaluating ^[13]. None of this changes what dose is right for you individually, but it explains why the pharmacy's math (concentration times volume) and a web calculator's math (weight times mcg/kg) are answering different questions. If you're at the stage of actually reconstituting a vial and drawing a dose, the practical step-by-step lives in our guide to reconstitute cjc ipamorelin, which walks through diluent volume, concentration math, and syringe markings, the part a generic calculator can't help with at all.

How does an ipamorelin dose compare to a CJC-1295 dose?

They're usually discussed together because they're often used together, but they're different molecules with different half-lives and different dosing logic, so one calculator rarely fits both well. Ipamorelin is a short-acting ghrelin mimetic; a 1998 study in the European Journal of Endocrinology characterized it as selective for GH release with a short pharmacokinetic profile ^[2], and a 1998 pharmacokinetic paper in Xenobiotica looked specifically at nasal absorption and clearance of ipamorelin and related peptidyl secretagogues ^[14]. CJC-1295 (especially the DAC version) is a modified growth hormone-releasing hormone analog designed for a longer duration of action, which is a structurally and mechanistically different approach even though both ultimately push GH release upward. Because the two have different clearance profiles, a joint calculator has to make two separate assumptions, not double the same one. If you're specifically trying to work out a combined protocol, use the cjc-1295 ipamorelin dosage calculator rather than trying to add an ipamorelin-only number to a CJC-1295-only number by hand; the timing and frequency logic differs between the two compounds in ways a simple sum won't capture. Worth repeating here: neither compound has an FDA-approved combined dosing label. Whatever ratio or schedule you see cited (commonly something like a fixed mcg amount of each per injection in forum protocols) is not validated by a regulatory trial. Treat it as a starting question for a prescriber conversation, not an answer.

Are there safety limits a dosage calculator should build in?

A responsible calculator should flag known physiological effects rather than just outputting a number, but most don't, so you need to know the boundaries yourself. Ghrelin receptor agonists like ipamorelin affect more than the pituitary. A 2004 paper in Neuro Endocrinology Letters examined ipamorelin's mechanism of evoked insulin release in normal and diabetic rat pancreas tissue, which is relevant if you have any glucose handling concerns ^[15]. A 2001 paper in Biochemical and Biophysical Research Communications found GH-independent stimulation of adiposity by GH secretagogues in animal models, meaning some effects on fat tissue may not run through the growth hormone axis at all, which complicates simple dose-response assumptions ^[16]. On the injection-site and systemic side, a 2001 study in Growth Hormone & IGF Research found ipamorelin counteracted glucocorticoid-induced decreases in bone formation in adult rats ^[17], and a related 2000 study in the Journal of Endocrinology found ipamorelin and GHRP-6 increased bone mineral content in adult female rats ^[18]. These are interesting mechanistic findings, not license to assume higher doses are always better or that bone effects generalize cleanly to humans at self-selected doses. A 2026 Sports Medicine review on the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance is directly relevant to anyone dosing based on a forum number: it evaluates both approved and unapproved peptide use in this space, which is precisely the category ipamorelin sits in for most people searching a dosage calculator ^[19]. That review's existence is itself a signal: this is exactly the underregulated dosing territory where regulators and journals are now trying to catch up. If you want the fuller side-effect picture before you touch a syringe, read ipamorelin side effects first.

Can black-market or unregulated ipamorelin throw off dosing math entirely?

Yes, and this is arguably the biggest real-world risk a dosage calculator cannot fix. A calculator assumes the vial you're drawing from actually contains what the label says, at the concentration it claims. That assumption fails more often than people expect. A 2018 analysis in Growth Hormone & IGF Research tested new growth-promoting black market products and found problems with content and purity in products being sold outside legitimate pharmacy channels ^[20]. If a vial is underdosed, your calculator's careful mcg/kg math produces a real number applied to a fake concentration, and you end up under- or over-dosing without knowing it. If it's contaminated, the dose question becomes secondary to a bigger safety problem. This is the practical argument for sourcing through a legitimate, provider-reviewed pathway rather than an unregulated seller, whatever the calculator says the ideal dose should be. A correct dose from a wrong vial is not a correct dose. For more on what a legitimate sourcing path looks like, see buy ipamorelin.

Why is ipamorelin only available as part of a tesamorelin/ipamorelin blend?

There is no standalone ipamorelin product dispensed through the legitimate compounding pathway covered here. What's available is a compounded tesamorelin/ipamorelin blend, prescribed as a combined product rather than as two separate vials. This matters directly for dosage calculators, because a calculator that outputs 'ipamorelin: X mcg' as a standalone figure is describing a product that isn't actually what gets dispensed. The real-world dosing decision a prescriber and compounding pharmacy make is about the blend: the ratio of tesamorelin to ipamorelin in the formulation, and the total injection volume, not an ipamorelin number in isolation. Tesamorelin is worth noting separately because it does have FDA approval, for HIV-associated lipodystrophy, which gives it an actual dosing label in a way ipamorelin lacks. When the two are compounded together, the ipamorelin component still doesn't inherit an approved dose; it's added based on the prescriber's clinical judgment and the compounding pharmacy's formulation, working from the mechanistic and small-trial evidence discussed throughout this article, not from a label. If you want the fuller background on how ipamorelin itself is characterized in the literature before you think about blends, start with ipamorelin.

What should you actually do instead of trusting a calculator's number?

Use a calculator's output as a question, not an answer. Bring the number to a licensed prescriber and ask them to explain why it's higher, lower, or the same as what they'd actually prescribe given your labs and history. A legitimate provider-reviewed pathway means a real intake (often including bloodwork like IGF-1), a clinician who prescribes a specific concentration and schedule, and a pharmacy that dispenses to that prescription rather than to a self-selected calculator output. That's also the only pathway where you have any real recourse if something goes wrong with sourcing or purity, versus buying loose from an unregulated seller. For the general dosing framework, including how frequency and cycle length questions get answered by clinicians in practice, read ipamorelin dosage. It covers the injection-frequency and timing questions that a single calculator number can't answer on its own.

Frequently asked questions

How accurate is an online ipamorelin dosage calculator?

It's only as accurate as the assumption it's built on, and there is no FDA-approved human dosing label to build it from. Most calculators extrapolate from small pharmacology studies or forum protocols. Treat any output as a rough starting figure for a prescriber conversation, not a validated, personalized dose.

What is a typical ipamorelin dose in mcg per kg of body weight?

There's no established human mcg/kg standard. Research studies, including a 1999 pharmacokinetic modeling study in Pharmaceutical Research, characterized dose-response after single dosing in volunteers, but that's a research model, not a clinical dosing guideline for weight-based self-dosing.

Does ipamorelin dosage depend on body weight the way some drugs do?

Weight-based dosing makes sense for compounds with well-mapped dose-response curves in large trials. Ipamorelin lacks that kind of human data, so weight-based calculators are working from extrapolation, not from an established linear relationship validated in humans at the outcomes people typically care about.

Is there an FDA-approved ipamorelin dose I can look up?

No. Drugs@FDA, the FDA's approved drug products database, does not list an approved ipamorelin product, so there is no official label or approved dosing table to reference for it.

Why is ipamorelin sold as a tesamorelin/ipamorelin blend instead of alone?

Legitimate compounding pathways dispense ipamorelin as part of a compounded tesamorelin/ipamorelin blend rather than as a standalone product. There is no standalone ipamorelin SKU through that route; the dosing decision covers the blend and ratio, set by the prescriber and pharmacy.

Can a dosage calculator account for a compounding pharmacy's specific vial concentration?

No. A generic calculator doesn't know your specific vial's concentration or your reconstitution volume. That math has to be done separately, using the actual label on your vial, which is why reconstitution guidance is a distinct step from any weight-based calculator output.

What doses were used in ipamorelin animal studies?

Rodent studies, including a 1999 rat study on longitudinal bone growth and a 2001 study on glucocorticoid-induced bone loss, used repeated subcutaneous mcg/kg dosing scaled to rat physiology. These don't translate directly to human mcg amounts on a simple per-kg basis.

Is there a human clinical trial that establishes an ipamorelin treatment dose?

The closest is a 2014 randomized, controlled proof-of-concept trial testing ipamorelin for postoperative ileus after bowel resection, which used a fixed clinical schedule for a GI motility endpoint. It's not a body-composition or anti-aging dosing trial, which is what most calculator searches are really after.

How does CJC-1295 dosing differ from ipamorelin dosing in a combined calculator?

CJC-1295 is a longer-acting GHRH analog with a different clearance profile than the short-acting ghrelin mimetic ipamorelin. A joint calculator has to model two separate pharmacokinetic assumptions, more than add two single-compound numbers together, which is why dedicated combined calculators exist.

Are black-market ipamorelin products a dosing risk even if I calculate the right amount?

Yes. A 2018 analysis in Growth Hormone & IGF Research found purity and content problems in black-market growth-promoting products. A calculator can't fix an inaccurate vial concentration; the correct math applied to a mislabeled product still produces an unknown real-world dose.

Does ipamorelin dosing need to account for insulin or glucose effects?

It's a relevant question to raise with a prescriber. A 2004 study in Neuro Endocrinology Letters examined ipamorelin's mechanism of insulin release in normal and diabetic rat pancreas tissue, suggesting metabolic effects worth discussing if you have glucose-handling concerns, though this was an animal mechanism study, not a human dosing trial.

Who should actually set my ipamorelin dose instead of a calculator?

A licensed prescriber working from your labs (commonly including IGF-1) and health history, paired with a legitimate compounding pharmacy dispensing to that specific prescription. That combination accounts for your actual vial concentration and clinical picture in a way no generic web calculator can.

Sources

1. Pharmaceutical Research, 1999 (PMID 10496658): A PK/PD model relating single ipamorelin doses to acute growth hormone release in human volunteers
2. European Journal of Endocrinology, 1998 (PMID 9849822): Ipamorelin is characterized as the first selective growth hormone secretagogue with minimal effect on cortisol, prolactin, and ACTH
3. Growth Hormone & IGF Research, 1999 (PMID 10373343): Ipamorelin induced longitudinal bone growth in young rats using repeated subcutaneous dosing
4. Histology and Histopathology, 2002 (PMID 12168778): Chronic ipamorelin treatment in young female rats produced a characterized somatotroph response in vitro
5. International Journal of Colorectal Disease, 2014 (PMID 25331030): A randomized controlled proof-of-concept trial tested ipamorelin for postoperative ileus after bowel resection using a fixed clinical dosing schedule
6. Drugs@FDA, FDA-approved drug products database: No FDA-approved ipamorelin drug product is listed in the agency's approved drug products database
7. JAAOS Global Research & Reviews, 2026 (PMID 41490200): A review of therapeutic peptides in orthopaedics notes the gap between preclinical promise and clinical dosing validation
8. American Journal of Sports Medicine, 2026 (PMID 41476424): A primer for orthopaedic and sports medicine physicians notes injectable peptide clinical use is outpacing dosing evidence
9. 21 U.S.C. 353a, pharmacy compounding: Compounded drug preparations, including tesamorelin/ipamorelin blends, are governed by the federal pharmacy compounding statute
10. Translational Andrology and Urology, 2020 (PMID 32257855): A review discusses growth hormone secretagogues as a category for body composition management in hypogonadal males
11. 21 CFR 216.23, the 503A Bulks List: Bulk drug substances used in 503A pharmacy compounding are governed by a specific FDA regulation
12. 21 CFR 216.24, the 503B Bulks List: 503B outsourcing facilities operate under a separate FDA bulk substances list from 503A pharmacies
13. FDA, bulk drug substances nominated for use in compounding: FDA maintains a running list of substances nominated for evaluation for compounding use
14. Xenobiotica, 1998 (PMID 9879640): A pharmacokinetic evaluation characterized ipamorelin absorption and clearance, including via the nasal route
15. Neuro Endocrinology Letters, 2004 (PMID 15665799): A study examined the mechanism of ipamorelin-evoked insulin release in normal and diabetic rat pancreas tissue
16. Biochemical and Biophysical Research Communications, 2001 (PMID 11162489): GH secretagogues stimulated adiposity in a growth-hormone-independent manner in animal models
17. Growth Hormone & IGF Research, 2001 (PMID 11735244): Ipamorelin counteracted glucocorticoid-induced decreases in bone formation in adult rats
18. Journal of Endocrinology, 2000 (PMID 10828840): Ipamorelin and GHRP-6 increased bone mineral content in adult female rats
19. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): A review evaluates safety and efficacy of both approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance
20. Growth Hormone & IGF Research, 2018 (PMID 29864719): Analysis of black market growth-promoting products found purity and content problems